Gufic BioSciences Ltd. — Interim / Quarterly Report 2023

Nov 11, 2022

==> picture [591 x 85] intentionally omitted <==

172/LG/SE/NOV/2022/GBSL

November 11, 2022

To To The Listing Department The Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code : 509079 Scrip Symbol : GUFICBIO

Dear Sir/Madam,

Subject: Outcome of the Board of Directors Meeting held on Friday, November 11, 2022

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Friday, November 11, 2022, inter alia Un-Audited Financial Results for the quarter and half year ended September 30, 2022.

In this regard, we are enclosing herewith the following:

1. Un-Audited Financial Results for the Quarter and Half Year ended September 30, 2022

2. Limited Review Report received from the Statutory Auditor of the Company on the Un-Audited Financial Results for the Quarter and Half Year ended September 30, 2022.

3. Investor Presentation on the Financial Results.

The meeting of the Board of Directors commenced at 3:00 p.m. and concluded at 7:10 p.m.

Kindly take the same on your record.

Thanking You, Yours truly, For Gufic Biosciences Limited

AMI Digitally signed by AMI SHAH SHAH Date: 2022.11.11 19:14:20 +05'30' Ami Shah Company Secretary & Compliance Officer Membership No. A39579

==> picture [57 x 59] intentionally omitted <==

Encl.: As above

==> picture [585 x 62] intentionally omitted <==

==> picture [48 x 8] intentionally omitted <==

==> picture [49 x 35] intentionally omitted <==

GUFIC BIOSCfENCES LIMITED

Regd. Office: 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East). Mumbai - 400069 (GIN- L24100MH1984PLC033519)

Website - w.qufic.com. email - info@guficbio.com. Ph-022 67261000. Fax - 022 67261068

	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)	Statement of Unaudited FinancialResults-forthe Quarer and Half Year Ended September 30, 2022 (s. in Lakhs except EPS)
1]	Sr. Pariculars No.				Quarer Ended				HalfYearEnded Yearended
					30-Sep-22		30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21 31-Mar-22
					Unaudited		Unaudited	Unaudited	Unaudited	Unaudited Audited
	1		INCOME
			aRevenue from operations		17,483.53		16,527.63	19,413.94	34,011.16	44,489.71 77,915.56
			b Other income		81.84 17,565.37		37.47 16,565.10	30.50 19,444.44	119.31 34,130.47	153.32 310.42 44,643.03 78,225.98
			Total Income
	2		Expenses
			a Cost of materials consumed			10,045.35	6,311.38	8,895.08	16,356.73	20,156.66 35,393.40
			b Purchase of stock-in-trade			631.15	677.05	1,873.17	1,308.90	5,417.28 7,741.84
				Changes in inventories of finished goods, work-in-progress and stock-in- trade		(2,138.76)	764.73	(282.09)	(1,374.03)	(310.56) (1,938.86)
		d		Employee benefits expense		2,012.53	2,142.73	2,011.63	4,155.26	4,559.49 8,561.18
		eFinance cost				160.64	90.83	154.87	251.47	275.81 484.68
		f Depreciation and amortisation expense				456.43	436.50	419.68	892.93	832.26 1,713.38
		qOther expenses				3,671.31 14,839.35 2,726.02	3,313.85 13,737.07 2,828.03	3,333.19 16,405.54 3,038.90	6,985.16 28,576.42 5,554.05	6,519.07 13,586.53 37,450.02 65,542.15 7,193.01 12,683.83
				Total Expenses
	3			Total Profit/ (Loss)before exceptionalitems.and tax (1-2)
	4			Exceptional items		-	-	-	~~-~~	- -
	5			Total Profit/ (Loss) Before Tax		2,72(.02	2,828.03	.3,038.90	5,554.05	7,193.01 12,683.83
	6			Tax expense
				Current tax		770.00	736.00	767.00	1,506.00	1,823.00 3,215.00
				Deferred tax		(65.13)	(13 12)	(61 72)	(78.25)	(84.31) (115.18)
				Short/(excess)taxprovision of earlieryears		~~-~~ 704.87 2,021.15	~~'~~ 722.88 2,105.15	- 705.28 2,333.62	~~- . ~~ 1,427.75 4,126.30	~~-~~ - 1,738.69 3,099.82 5,454.32 9,584.01
				Total Tax Expenses
	7			Net ProfitI(Loss) for the period from continuing operations
	8			Total Profit/ (Loss) for period		2,021.15	2,105.15	2,333.62	4,126.30	5,454.32	9,584.01
	9			Other Compr_ehensive Income (OCI)
				Items that will not be reclassified to Profit or Loss		~~-~~	-	-	-	-	(58.88)
				Less: Income tax relating to items that will not be reclassified to Profit or Loss		-	-	-	-	-	14.82
				Other Comprehensive income/ Loss (net of taxes)		~~-~~	~~-~~	-	-	-	(44.06)
	10			Total Comprehensive Income		2,021.15	2,105.15	2,333.62	4,126.30	5,454.32	9,539.95
	11			Othe Equity Reserves ..							25,942.35
	12			Details of Equity Share Capit,l
				Paid-up equity share capital		969.45	969.45	969.45	969.45	969.45	969.45
				Face value of equity share capital(Rs.)		1.00	1.00	1.00	1.00	1.00	1.00
	13			Earning per equity share
			i	Basic earnings/(loss) per share from continuing and discontinued operations		2.09	2.17	2.41	4.26	5.63	9.89
			ii	Diluted earnings/(loss) per share from continuing and discontinued operations		2.09	2.17	2.41	4.26	5.63 9.89

Notes:

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of companies Act, 2013, read with rules issued thereunder.

2. The above results for the quarter ended September 30, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors.at their meetings held on November 11, 2022.The Statutor:y Auditors have carried out limited review of the results for quarter and half-year ended September 30, 2022.

3. The Company"s business activity falls within a single operating segment i.e. Pharmaceuticals.

4. Previous year figures have been regrouped/ reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

==> picture [79 x 79] intentionally omitted <==

CEO & WHOLE TIME DIRECTOR DIN : 00001731

PLACE : MUMBAI DATE : 11/11/2022

==> picture [175 x 108] intentionally omitted <==

-- --·

==> picture [48 x 8] intentionally omitted <==

==> picture [80 x 17] intentionally omitted <==

G,UFIC - BlOSCfENCES ·LIMITED

Regd. Office 37, Kamala Elhavan 11, S. Nityanand Road, Andheri (East), Mumbai· 400069 (CIN- L24100MH1984PLC033519) Website - www.gufic.com email - info@guficbio.com, Ph-022 67261000. Fax - 022 67261068

2) Unaudited Balance sheet Particulars	as at �eptember 30, 2022 As at September 30, As at March 31, 2022 2022 (Unaudited) (Audited) 12,096.52 11.175.64 73.48 61.02 6,211.69 4,087.42 145.22 280.03 55.31 - 78.43 0.75 19.41 24.07 877.78 908.49 6,447.93 3,527.35 26,005.77 20,064.77 16,817.83 11,556.69 - - 18,822.49 15,155.29 2,948.74 1,16Q.80 1,677.94 1,496.31 60.88 38.26 3,161.36 2,668.05 43,489.24 32,075.40 69,495.01 52,140.17 969.45 969.45 29,967.70 25,942.35 30,937.15 26,911.80 11,177.37 4,739.73 499.75 499.75 18.78 32.88 1,408.10 1,238.86 - 18,95 13,104.00 6,530.17 7,207.14 659.92 642.97 698.98 13,858.83 13,396.14 1,078.62 1,868.23 142.09 281.65 526.88 487.15 1,256.76 1,238.66 740.57 67.48 25,453.86 18,698.21 38,557.86 25,228.37 69,495.01 52,140.17 ; - - ��(ARW4( � tC ��I 91 tFR. 5" "') ,' '�-r -�" �ed Acco� - iye��, f' D � ..- �a I�MUM �, �	as at �eptember 30, 2022 As at September 30, As at March 31, 2022 2022 (Unaudited) (Audited) 12,096.52 11.175.64 73.48 61.02 6,211.69 4,087.42 145.22 280.03 55.31 - 78.43 0.75 19.41 24.07 877.78 908.49 6,447.93 3,527.35 26,005.77 20,064.77 16,817.83 11,556.69 - - 18,822.49 15,155.29 2,948.74 1,16Q.80 1,677.94 1,496.31 60.88 38.26 3,161.36 2,668.05 43,489.24 32,075.40 69,495.01 52,140.17 969.45 969.45 29,967.70 25,942.35 30,937.15 26,911.80 11,177.37 4,739.73 499.75 499.75 18.78 32.88 1,408.10 1,238.86 - 18,95 13,104.00 6,530.17 7,207.14 659.92 642.97 698.98 13,858.83 13,396.14 1,078.62 1,868.23 142.09 281.65 526.88 487.15 1,256.76 1,238.66 740.57 67.48 25,453.86 18,698.21 38,557.86 25,228.37 69,495.01 52,140.17 ; - - ��(ARW4( � tC ��I 91 tFR. 5" "') ,' '�-r -�" �ed Acco� - iye��, f' D � ..- �a I�MUM �, �
	As at September 30, 2022 (Unaudited)	As at March 31, 2022 (Audited)
ASSETS Non-Current Assets Property. plant and equipment Intangible assets Capital work-in-progress Right of use assets Deferred tax assets (net) FinancialAssets i. Investments ii. Loans iii. Other financial assets Other non-current assets ! Total Non-Current Assets Current Assets Inventories Financial Assets i. Investments ii. Trade reciveables iii. Cash and cash equivalent iv. Bank balances v. Loans Other current assets Total_ Current Assets TOTAL ASSETS EQUITY AND LIABILITIES Equity Equity share capital Other equity Total Equity Liabilities Non-Current Liabilities Financial Liabilities i. Borrowings ii. Other FinancialLiabilities iii. Lease liability Provisions Deferred tax liabilhies (net) Total Non- Current Liabilities Current Liabilities Financial liabilities i. Borrowings ii. Trade payables Total outstanding dues of micro enterprises and small enterprises Total outstanding dues of other than micro enterprises and small enterprises iii. Other financial liabilities iv. Lease liability Provisions Other current liabilities Current tax liabilities·(net) Total Current Liabilities Total Liabilities TOTAL EQUITY AND LIABILITIES	12,096.52 73.48 6,211.69 145.22 55.31 78.43 19.41 877.78 6,447.93	11.175.64 61.02 4,087.42 280.03 - 0.75 24.07 908.49 3,527.35
	26,005.77	20,064.77
	16,817.83 - 18,822.49 2,948.74 1,677.94 60.88 3,161.36	11,556.69 - 15,155.29 1,16Q.80 1,496.31 38.26 2,668.05
	43,489.24 69,495.01	32,075.40 52,140.17
	969.45 29,967.70	969.45 25,942.35
	30,937.15	26,911.80
	11,177.37 499.75 18.78 1,408.10 -	4,739.73 499.75 32.88 1,238.86 18,95
	13,104.00	6,530.17
	7,207.14 642.97 13,858.83 1,078.62 142.09 526.88 1,256.76 74057	659.92 698.98 13,396.14 1,868.23 281.65 487.15 1,238.66 6748
	.
	25,453.86
	38,557.86

..... -.... -

==> picture [48 x 8] intentionally omitted <==

Gutic Bkisden.ces Limited

Statement of cash flows for the H;,lf-year ended September 30, 2022

==> picture [41 x 7] intentionally omitted <==

Ail amounts are in Rs. Lakhs unles� otherwise stated

3]	Particulars	For the HalfYear ended September 30, 2022 (Unaudited)	For the Half-Year ended September 30, 2021 (Unaudited)
	A. Cash flows from operating activities Profit for the year Adjustments for: Income tax expense recognised in profit or loss Depreciation Dividend Interest income on fixed deposits witll banks Interest income on financial assets carried at amortised cost Interest costs on financial liabilities measured at amortised cost Non current security deposits at amortised cost Profit on sale of fixed asset Sundry credit balances written back Operating profit before movments in tile working capital Movements in working capital: (lncrease)/decrease in trade and other receivables (lncrease)/decrease in inventories Increase/ (Decrease) in trade and other payables Cash generated from operations Income taxes paid Net cash generated from operating activities (A) 8. Cash flows from investing activities Purchase of property, plant and equipments including capital advances Purchase of intangibles Sale of property, plant and equipments Other dividend received Investment in equity Fixed Deposit with Banks Balance in earmarked accounts Interest income on fixed deposits with banks Net cash used in investing activities (8) C. Cash flows from financing activities Proceeds_I_(Repayment) from current borrowings Proceeds_I_(Repayment) from non current borrowings Processing fees paid Payment on lease liabilities Payment for Interest lease liability Dividends paid on equity shares Interest paid Net cash generated from financing activities (C) Net increase in cash and cash eq!livalents (A+ 8+C) Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the September,22	4,126.30 1,427.75 892.93 (0.05) (33.36) (28.64) 251.47 23.36 (11.03)	5,454.32 1,738.69 832.26 (35.02) (47.01) 275.81 36.16 (6.71) 7.83
		6,648.73 (4,000.21) (5,261.14) 429.72	8,256.33 (2,172.08) (2,107.08) 8,283.03
		(8,831.63) (2,182.90) (832.91)	• 4,003.87 12,260.20 (1,282.19) 10,978.01 (2,617.15) - 13.45 - - (4,500.00) (899.70) 10.28 (7,993.12) (1,632.43) (258.62) - (142.61) (32.37) (96.94) (267.33)
		(3,015.81) (6,708.29) 0.05 (77.68) (201.24) 52.97
		(6,934.19) 5,822.66 6,437.64 (153.67) (14.33) (96.76) (257.60)
		11,737.94	(2,430.30) 554.59 620.14
		1,787.94 1,160.80
		2,948.74	1,174.73

==> picture [200 x 112] intentionally omitted <==

==> picture [156 x 83] intentionally omitted <==

MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

==> picture [64 x 44] intentionally omitted <==

as amended to Regulat10n 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, Limited R�view Report on the Unaudited Quarterly Financial Results of the Company Pursuant

Review Report to The Board of Directors Gufic Biosciences Limited

• We have reviewed the accompanying statement of Unaudited Financial Results of Gufic Biosciences Limited (the "Company") for the quarter ended and six months ended 30 September 2022 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

• 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our r sponsibility is to issue a report on the Statement based on our review.

• 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not e press an audit opinion.

• 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.

Place: Mumbai Dated: 11 / 1112022 UDIN: 2 J 3 r 1) E,(_,)/. v� �-1

==> picture [82 x 86] intentionally omitted <==

For Mittal Agarwal & Company Chartered Accountants (Firm Registration No. 131025W f � Piy h Agarwal {s P rtner M mb r hip N . 1 55 5

==> picture [54 x 5] intentionally omitted <==

Regd. Office: 404, Madhu Industrial Estate, Mogra Cross Road, Near Apollo Chamb�rs, Andheri (E), Mumbai - 400 069; Ph - 022 2832 4532/34; Fax - 022 2830 4533; Email - office@m1ttalagarwal.com

Delivering Care & Cure

Investor Presentation November 2022

==> picture [56 x 41] intentionally omitted <==

Safe Harbor

==> picture [81 x 76] intentionally omitted <==

This presentation has been prepared by and is the sole responsibility of Gufic Biosciences Limited (the “Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Certain statements contained in this presentation that are not statements of historical fact constitute “forward-looking statements.” You can generally identify forward looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.

2

==> picture [169 x 158] intentionally omitted <==

H1 FY23 Business & Financial Highlights

==> picture [56 x 41] intentionally omitted <==

H1 FY23 Business Highlights

Gearing up for Indore Facility to go live

• Started investing in R&D for new molecules and drug delivery systems which will eventually smoothen the entire journey of going live at Indore

• Planned validation batches to create data and build up dossiers for the pipeline products which should help us reduce the time to market

Critical Care Division

• Retained leadership position in Anti fungals & Anti bacterials

• Launch of a sub-division – Sparsh. This will use the most advance technology to smoothen the supply chain process for delivering 100+ high quality injectable products to untapped hospitals and nursing homes including the sub-urban and rural market. Addressable market size is ~Rs. 9,500 crores, growing at a CAGR of 12%

• DCGI Approval received for manufacturing and marketing of Biapenem Dual Chamber Bag

• Critical Care segment faced headwinds due to reduced hospitalization and excess inventory in the channel

• Planning to launch Ceftazidime + Avibactam soon. Gufic will be the only Indian Company to launch this product other than the innovator with inhouse manufactured API (Avibactam)

• Launching the novel ‘Once a week’ anti-infective - Dalbavancin for the 1[st] time in India in Q4 FY23

• DCGI approval received to conduct Phase III Clinical trials for Thymosin Alpha injection in Sepsis

==> picture [81 x 76] intentionally omitted <==

Domestic Business Breakup

==> picture [162 x 149] intentionally omitted <==

Critical Care Division Infertility Division Others

Total Revenue Breakup

==> picture [160 x 148] intentionally omitted <==

Domestic Business International Business CMO Bulk Drugs & API

4

==> picture [56 x 41] intentionally omitted <==

H1 FY23 Business Highlights

==> picture [81 x 76] intentionally omitted <==

Ferticare Division

• The divisions continues to register high double-digit growth for female infertility hormones such as Puregraf (HMG) and Puretrig (HCG)

• DCGI approval received to conduct Phase III Clinical trials for Thymosin Alpha injection in Endometriosis

• Dydrogesterone: This product has been launched. Further, to de-risk the short supply of API, Gufic has vertically integrated to manufacture its own API. Market size for this product is ~Rs. 800+ crores growing at 60% YoY

• Gufic has invested to develop recombinant alternatives to the urinary source of certain hormones which are critical in the treatment of infertility and thereby ensuring we will be independent of geopolitical as well as currency exchange risks and potential pitfalls in the next 12-18 months

• Gufic continues to increase its penetration for Enoxaparin in the infertility segment

• Gufic has registered 2[nd] Rank in the high growing Cetrorelix market

Healthcare, Stellar & Spark Division

• We initiated trial of a new product made from an Indian gum by a standardized extraction process for use in the management of asthma

• Our brand Sallaki continues to be the market leader in Boswellia Serrata market

• A new multivitamin formulation has been launched which should do well in the coming quarters aiding growth in this segment

• Launched a cannabis extract based topical solution for muscular and arthritic pain relief

• Initiated development of a unique liposomal iron formulation

5

==> picture [56 x 41] intentionally omitted <==

H1 FY23 Business Highlights

International Business

• Have seen growth of ~25% through International Business. 190+ Products are now registered across regulated and semi-regulated markets

• Another 150+ products are in pipeline for registration in over 40 countries

• 2 new product approvals received from each, UK-MHRA and ANVIZABrazil. Also, received 1 product approval from Health Canada

• Multiple products in pipeline for registration across regulated markets

• For Europe and LATAM, strategy is in place to register existing developed formulations in countries in which we have presence and enter new countries based on market gaps and opportunities

To augment Gufic’s global strategic alliances, we participated in CPhI 2022 held at Frankfurt, Germany

==> picture [81 x 76] intentionally omitted <==

==> picture [423 x 383] intentionally omitted <==

6

==> picture [56 x 41] intentionally omitted <==

H1 FY23 Business Highlights

==> picture [81 x 76] intentionally omitted <==

Arisia, The Center of Excellence in Mumbai

• Most advanced aesthetic clinic and training center designed to raise the standards of aesthetic clinics with excellence in services

• Through the center of excellence, we aim to offer comprehensive quality aesthetic services under one roof through patient centric care ensuring patient safety, privacy and dignity

• The multiple spacious treatment rooms are equipped with cutting edge FDA approved technologies to provide the best non surgical cosmetic care

• Moreover, the knowledge repository of the centre will be made open and available to all the members of the medical fraternity across fields, specializations and philosophies to leverage our findings, thus making available the magnificent and marvelous capabilities of botulinum toxin to the society at large

• The 20+ aesthetic procedure combinations will offer skin and body transformation through FDA approved technologies

Aestherderm Division

• Stunnox continues to increase penetration in the market. We are developing fillers to complement and complete this basket

• Started the training center for new therapies with combination of machines and use of fillers and Botulinum Toxin for face and body contouring

• Gufic has partnered with Indian College of Cosmetic Gynaecology (ICCG) in the field of cosmetic vaginal tightening and rejuvenation and organized trainings to promote the use of Botulinum Toxin for these indications

7

==> picture [81 x 76] intentionally omitted <==

==> picture [56 x 41] intentionally omitted <==

Innovation at Gufic

==> picture [960 x 9] intentionally omitted <==

Update on Research & Development and Innovation

==> picture [960 x 10] intentionally omitted <==

• The API Research Development at Navsari has made noteworthy progress in development of molecules in therapeutic categories such as Antifungal, Anticoagulant, Tetracycline Antibiotics, Progestin, Beta 3 adrenegic agonists, Antidiabetic, Cyclopeptides Hormones. These development projects are all progressing in line with the plan

• Break-through in the development of novel topical formulation of Botulinum Toxin for the first time in the world

• A wide range of products being developed in the new drug delivery system of Dual Chamber Syringes which will ensure ease of reconstitution, accurate dosing and maintain sterility from plant to patient

• Isavuconazole oral option to compliment the injectable by Q3 FY23. The overall market of this molecule is growing at 100%

Selvax Update

• The Selvax immunotherapy demonstrated promising results (100% long-term cures alongside induction of protective immunity) in the two pancreatic cancer models tested in the pre-clinical stage. These results align with the other different mouse tumour models tested

• Moreover, it has consistently outperformed FDA approved checkpoint inhibitors which have become first line therapies for some cancers, including melanoma. These results indicate that the Selvax immunotherapeutic approach could offer a viable alternative to existing therapies for the treatment of pancreatic cancer

• Current treatment options for pancreatic cancer include surgery, chemotherapy, radiotherapy, and ablation. These options are rarely effective, and in most cases are used to manage symptoms rather than eradicate disease, highlighting a dire need for new treatments that are effective at combating a cancer that is currently incurable

8

==> picture [81 x 76] intentionally omitted <==

==> picture [56 x 41] intentionally omitted <==

Strategic Initiatives

==> picture [960 x 9] intentionally omitted <==

Strategic Initiatives that will further amplify growth over the next few years

==> picture [960 x 10] intentionally omitted <==

Increase in overall market and market share in Botulinum Toxin range of products through introduction of fast acting injectable and topical formulation (first in India and world)

Leverage new biological technology platform to Commercialization of develop preventive and immuno-oncology therapy curative medical care for fatal viral infections

Increase market share in contract manufacturing beyond paranterals to other drug delivery systems

9

==> picture [56 x 41] intentionally omitted <==

Profit & Loss Statement

==> picture [81 x 76] intentionally omitted <==

Particulars (in Rs. Crore)	Q2 FY23	Q1 FY22	Q2 FY22*
Total Revenue	175.7	165.7	194.4
EBITDA	33.4	33.6	36.1
EBITDA Margin %	19.0%	20.3%	18.6%
Profit before Tax	27.3	28.3	30.4
PBT Margins %	15.5%	17.1%	15.6%
Tax	7.0	7.2	7.1
Profit After Tax	20.2	21.1	23.3
PAT Margin %	11.5%	12.7%	12.0%

• Sales were higher in Q2 FY22 due to an increased CoVID-19 product portfolio

10

==> picture [122 x 84] intentionally omitted <==

Company Overview

==> picture [56 x 41] intentionally omitted <==

About Gufic Biosciences

==> picture [81 x 76] intentionally omitted <==

==> picture [960 x 9] intentionally omitted <==

Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products

==> picture [960 x 9] intentionally omitted <==

One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas

DOMESTIC BUSINESS CMO BUSINESS BULK DRUG BUSINESS 8 well defined One of the largest Exclusive facility for Strategic Business facility for API Units Lyophilization Specialization in Field force of ~1,000+ 70+ CMO Partners • Anesthetics Product Portfolio in 50+ Products • Anti Fungal 15+ Therapy Areas • Antibiotic

INTERNATIONAL BUSINESS

Operation spread across more than 20 countries 130+ Products registered globally 150+ products in pipeline for registration

Moving in the right direction...with a well-defined business structure

12

==> picture [56 x 41] intentionally omitted <==

World Class Manufacturing Infrastructure

==> picture [81 x 76] intentionally omitted <==

Unit - I at Navsari

Botulinum Toxin Facility

Lyophilized/Powder Injectables Facility Natural Products (Topical/Liquid)

API Facility

Capacities

==> picture [182 x 10] intentionally omitted <==

• ✓ Lyophilized – 18 mn vials p.a.

Unit - II at Navsari

Lyophilized Injectables Facility

Capability to manufacture Liposomal Amphotericin B and Depot Injections

Capacities

==> picture [182 x 10] intentionally omitted <==

✓ Lyophilized – 30mn vials p.a.

✓ PFS – 30mn PFS p.a.

Gufic - Belgaum

Natural Products Facility

Capacities

==> picture [182 x 10] intentionally omitted <==

✓ 60mn capsules p.a.

  - ✓ 3.6mn powder p.a.

• ✓ Ampoule – 12mn p.a.

• ✓ Ointment – 6mn tubes p.a.

✓ Lotion – 6mn bottles p.a.

WHO GMP, Philippines BFAD, Nigeria NAFDAC, Cambodia MOH, Kenya PPB, Ethiopia FMHACA, Thailand MOH, Sri Lanka NMRA

✓ Syrup – 6mn bottles p.a. ✓ PFS – 2.8mn PFS p.a.

EU GMP (Hungary), ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA, Uganda NDA, SAHPRA South Africa

13

==> picture [56 x 41] intentionally omitted <==

Upcoming World Class Manufacturing Infrastructure

==> picture [81 x 76] intentionally omitted <==

Unit - III at Indore

Penem Block

UPDATE ON CAPEX

Indore

Lyophilized/Powder Injectables Facility

Capability to cater to regulated markets such as US & EU

Dedicated facility for Penem

Carbapenems (Lyophilized / Dry

Powder Inj / Oral Solids / Dual Chamber Bags)

Civil Construction and Site Development work is progressing as per schedule and is near completion

All equipment have been selected and orders have been placed and we expect it to reach us by September

Expected commercialization by Q1 FY24

Capacities

==> picture [182 x 10] intentionally omitted <==

✓ Lyophilized – 36 mn vials p.a. ✓ PFS – 15mn PFS p.a.

✓ Liquid Injections – 60mn units p.a.

Capacities

==> picture [182 x 10] intentionally omitted <==

✓ Lyophilized – 3mn vials p.a.

✓ Dual Chamber Bags 24 mn IV bags

✓ Dry Powder Inj 30 mn Vials

Penem Block at Navsari

Strategic decision to move the penem block to Navsari to reduce the time to market turned out well

Civil work complete, Equipment received and Installation complete

Commercialization has begun as announced earlier

Moving in the right direction... To scale up the manufacturing facility

14

==> picture [56 x 41] intentionally omitted <==

Botulinum Toxin Facility

==> picture [81 x 76] intentionally omitted <==

Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari

==> picture [26 x 18] intentionally omitted <==

==> picture [26 x 19] intentionally omitted <==

==> picture [26 x 19] intentionally omitted <==

==> picture [72 x 65] intentionally omitted <==

==> picture [91 x 62] intentionally omitted <==

Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and efficacy of Botulinum toxin

Gufic and Prime bio, to develop several innovative formulations with Botulinum toxin in the field Dermatology, Neurology and Pain Management

==> picture [500 x 296] intentionally omitted <==

15

==> picture [56 x 41] intentionally omitted <==

Consolidating the Domestic Branded Business

==> picture [81 x 76] intentionally omitted <==

Products

CRITICAL CARE

INFERTILITY

MASS SPECIALITY

100+

SKU’s

200+

Prescribers

30,000+

Retail Reach

1,10,000+

Doctors Reach

1,20,000+

Hospital Coverage

==> picture [16 x 12] intentionally omitted <==

80 % of Tertiary care,

==> picture [65 x 47] intentionally omitted <==

Field Force: 250

==> picture [12 x 9] intentionally omitted <==

Therapy Areas: Antibacterial, Antifungal, Pain Management, Blood products, GI Immuno modulator

==> picture [12 x 10] intentionally omitted <==

NATURAL AND

NUTRACEUTICAL PRODUCTS

==> picture [92 x 55] intentionally omitted <==

Field Force: >300

==> picture [13 x 10] intentionally omitted <==

Therapy Areas: Bone Health, Pain Management, Immunity, Gastro, Stress, Nutraceuticals, Wound care, Respiratory, Gynaec

==> picture [13 x 10] intentionally omitted <==

==> picture [13 x 9] intentionally omitted <==

==> picture [13 x 10] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

==> picture [94 x 44] intentionally omitted <==

Field Force: >150

Therapy Areas: Hormones, Recombinant Products, Infertility Supplements

ORTHO – GYNAEC PRODUCTS

==> picture [87 x 52] intentionally omitted <==

Field Force: >60

Therapy Areas: Bone Health, Pain Management, Fractures, Arthritis, Pregnancy, Post Menopausal

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 10] intentionally omitted <==

==> picture [12 x 10] intentionally omitted <==

==> picture [12 x 10] intentionally omitted <==

==> picture [74 x 49] intentionally omitted <==

Field Force: >180

Therapy Areas: Anti Infectives, Gastro, Gynaecology, Respiratory, Nutraceuticals, Dermaology

DERMO – COSMECTICS PRODUCTS

==> picture [132 x 37] intentionally omitted <==

Field Force: >40

Therapy Areas: Neurotoxin, Emollients, Antiaging, Cleansers, Pre & Post Procedure, Hyperpigmentation, Sunscreens

==> picture [16 x 12] intentionally omitted <==

Presence in Government Institutions

Venturing into new futuristic therapy areas : Biologicals and Immuno-Oncology

16

==> picture [56 x 41] intentionally omitted <==

Expanding Creditability in CMO Business

==> picture [81 x 76] intentionally omitted <==

Offer CMO services Reliable CMO service for 70+ 150+ Products for India and quality products over a Global Markets Companies across multiple therapy areas decade

One of the Largest Supplier of Formulations

Liposomal Doxycycline Tigecycline Gonadotropins Micafungin Remdesivir Amphotericin B OUR ESTEEMED PARTNERS

==> picture [117 x 48] intentionally omitted <==

==> picture [221 x 33] intentionally omitted <==

==> picture [101 x 49] intentionally omitted <==

==> picture [42 x 57] intentionally omitted <==

==> picture [98 x 36] intentionally omitted <==

==> picture [66 x 23] intentionally omitted <==

==> picture [80 x 34] intentionally omitted <==

==> picture [61 x 46] intentionally omitted <==

==> picture [83 x 23] intentionally omitted <==

==> picture [77 x 45] intentionally omitted <==

==> picture [78 x 27] intentionally omitted <==

==> picture [78 x 37] intentionally omitted <==

==> picture [119 x 27] intentionally omitted <==

==> picture [111 x 39] intentionally omitted <==

==> picture [73 x 50] intentionally omitted <==

==> picture [73 x 41] intentionally omitted <==

17

==> picture [56 x 41] intentionally omitted <==

Expanding Geographical Reach

==> picture [756 x 330] intentionally omitted <==

----- Start of picture text -----

130+ Products registered
globally (in 15+ countries)
150+ Products in pipeline for
registration (in 30+ countries)
----- End of picture text -----

==> picture [22 x 16] intentionally omitted <==

==> picture [22 x 16] intentionally omitted <==

==> picture [81 x 76] intentionally omitted <==

CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZUELA | SUDAN | ETHIOPIA | ECUADOR | PERU | PARAGUAY | NIGERIA | SOUTH AFRICA | EGYPT ZIMBABWE | UGANDA | YEMEN | SRI LANKA | MYANMAR | PHILIPPINES | THAILAND | CAMBODIA | VIETNAM | MALAYSIA | UKRAINE JORDAN | SYRIA | GEORGIA | UZBEKISTAN | KAZAKHSTAN | NEPAL | RUSSIA | AUSTRALIA

18

==> picture [56 x 41] intentionally omitted <==

Building API Capabilities

Special Facility dedicated to API

==> picture [542 x 300] intentionally omitted <==

----- Start of picture text -----

Focused on developing non The categories of API’s
infringing, novel, cost manufactured are
effective and scalable antifungals, antibacterial,
chemical process for APIs, anesthetics and
Peptides and Cyclopeptides intermediates for antifungals
Presence in 25 countries
70 customers PAN India
worldwide
----- End of picture text -----

==> picture [298 x 470] intentionally omitted <==

19

==> picture [56 x 41] intentionally omitted <==

Strong Partnership & Licensing Deals

==> picture [81 x 76] intentionally omitted <==

==> picture [185 x 40] intentionally omitted <==

European leader in IV drug delivery systems. Collaborated with Gufic to launch Dual Chamber Bags for the 1[st] time in India for anti - infectives

Through our collaborations with global partners that are researching to expand the frontiers of pharma and biotechnology, Gufic will be a technology bridge to the future of healthcare and economical patient care in India

==> picture [60 x 54] intentionally omitted <==

==> picture [162 x 55] intentionally omitted <==

==> picture [110 x 66] intentionally omitted <==

==> picture [186 x 42] intentionally omitted <==

Therapy Area: Toxins Strain transfer, Tech transfer, formulation development and manufacturing at Gufic

Therapy Area: Recombinant products and Anti Infectives Collaboration on several API to develop new product

Therapy Area: Infertility Tech transfer and Clinical development(Phase III) of the product at Gufic

Therapy Area: Dermo Cosmetics Technical collaboration and Product Development

20

==> picture [56 x 41] intentionally omitted <==

Extensive Sales, Distribution IT Infrastructure in India

==> picture [226 x 127] intentionally omitted <==

2 Central Warehouses

located in North Delhi and West Bhiwandi

==> picture [260 x 12] intentionally omitted <==

==> picture [32 x 33] intentionally omitted <==

==> picture [81 x 76] intentionally omitted <==

Pan India Presence with a field force of 1,000+

==> picture [261 x 11] intentionally omitted <==

==> picture [32 x 33] intentionally omitted <==

IT Infrastructure

23 Carrying & Forwarding

(C&F) agents across India

==> picture [260 x 11] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

Stockists for 1,200+

effective distribution across India

==> picture [260 x 11] intentionally omitted <==

==> picture [25 x 18] intentionally omitted <==

==> picture [25 x 18] intentionally omitted <==

==> picture [25 x 19] intentionally omitted <==

Integrated IT Systems with Sales and Distribution Infrastructure

SAP S4 HANA (being Implemented) across all Departments

Tablets, Sales Force Automation and Effectiveness tools in place

Retail coverage of more than retailers 1,10,000

==> picture [261 x 12] intentionally omitted <==

==> picture [32 x 32] intentionally omitted <==

Doctors Reach of

1,20,000+

==> picture [261 x 11] intentionally omitted <==

21

==> picture [56 x 41] intentionally omitted <==

Growth Levers

==> picture [239 x 227] intentionally omitted <==

----- Start of picture text -----

1
INDIA BUSINESS
----- End of picture text -----

• Consolidation of the Critical Care Infertility business

• Entry into new therapy areas Dermatology - Aesthaderm

• Strategic focus on Healthcare division with entry into Ortho Gynecology products through a new division Stellar

==> picture [239 x 227] intentionally omitted <==

----- Start of picture text -----

2
INTERNATIONAL
BUSINESS
----- End of picture text -----

• Expand our presence in regulated markets such as US EU

• Gradually commercialize the pipeline products

• Explore newer geographical locations

==> picture [81 x 76] intentionally omitted <==

==> picture [238 x 227] intentionally omitted <==

----- Start of picture text -----

3
CMO BUSINESS
----- End of picture text -----

• Scale up the manufacturing capacity

• Consolidation of the clients offer more products to existing clients

• Expand the customer base

• New product offerings

• Build a robust pipeline of new products

• Build up the licensing products portfolio

==> picture [240 x 24] intentionally omitted <==

==> picture [240 x 24] intentionally omitted <==

==> picture [240 x 24] intentionally omitted <==

22

==> picture [56 x 41] intentionally omitted <==

Our Robust R&D and Clinical team to augment growth

==> picture [81 x 76] intentionally omitted <==

Research & Development (R&D)

Clinical Team

State-of-the-art R&D Facility in Navsari, Gujarat with expertise in

==> picture [396 x 9] intentionally omitted <==

Formulation Development

==> picture [13 x 10] intentionally omitted <==

Technology Transfer

==> picture [13 x 9] intentionally omitted <==

==> picture [13 x 10] intentionally omitted <==

API Development

Patents in various therapy areas

==> picture [214 x 10] intentionally omitted <==

Granted: 5 Filed/In-process of filling : 8

==> picture [13 x 9] intentionally omitted <==

==> picture [130 x 139] intentionally omitted <==

Special / NDDS Projects

Major Projects in Pipeline

==> picture [176 x 10] intentionally omitted <==

==> picture [176 x 10] intentionally omitted <==

50+ across all therapy areas

Innovative formulations of Botulinum Toxin

==> picture [13 x 9] intentionally omitted <==

Anti Infectives: 11

==> picture [13 x 10] intentionally omitted <==

• Liposomal Amphotericin-B Injection

• Dermatology: 7

==> picture [13 x 9] intentionally omitted <==

==> picture [13 x 9] intentionally omitted <==

==> picture [13 x 9] intentionally omitted <==

Gynaec: 6

Depot Injection CNS: 4 Dual Chamber IV Bags Anti Fungal: 3 Dual Chamber Syringes Oncology: 3

==> picture [13 x 10] intentionally omitted <==

==> picture [13 x 9] intentionally omitted <==

==> picture [13 x 9] intentionally omitted <==

Strong Clinical team comprising of

==> picture [219 x 10] intentionally omitted <==

Medical Regulatory Product Development

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 9] intentionally omitted <==

==> picture [12 x 10] intentionally omitted <==

Projects in various Clinical Phases

==> picture [204 x 10] intentionally omitted <==

Ongoing: 5

==> picture [12 x 9] intentionally omitted <==

Pipeline: 12

==> picture [12 x 9] intentionally omitted <==

Capabilities to take Synthetic and Biological Projects across Phase II and Phase III clinical trials

Pharmacovigilance Team

23

==> picture [122 x 84] intentionally omitted <==

Historical Financials

==> picture [56 x 41] intentionally omitted <==

Historical Financials

==> picture [81 x 76] intentionally omitted <==

==> picture [894 x 284] intentionally omitted <==

----- Start of picture text -----

Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin
12.7% 13.1% 13.8% 17.2% 19.1% 5.4% 6.3% 6.0% 9.1% 12.3%
779
149 96
488
379
351 84
306
44
52
46
39
22 23
16
2018 2019 2020 2021 FY22 2018 2019 2020 2021 FY22 2018 2019 2020 2021 FY22
----- End of picture text -----

CAGR 26%

CAGR 40%

CAGR 55%

In Rs. Crs.

25

==> picture [56 x 41] intentionally omitted <==

Historical Financials

==> picture [81 x 76] intentionally omitted <==

Particulars (Rs. Crs.)	FY22	FY21	FY20	FY19	FY18
Revenue from Operations	779.2	487.7	378.8	350.8	305.6
EBITDA	148.8	83.9	52.1	46.0	38.8
EBITDA Margin %	19.1%	17.2%	13.8%	13.1%	12.7%
Profit before Tax	126.8	57.7	30.1	35.3	30.0
PBT Margin %	16.3%	11.8%	7.9%	10.1%	9.8%
Tax	31.0	13.5	7.4	13.4	13.5
Profit After Tax	95.8	44.2	22.7	21.9	16.5
PAT Margin %	12.3%	9.1%	6.0%	6.3%	5.4%

26

==> picture [56 x 41] intentionally omitted <==

Historical Balance Sheet (Equity & Liabilities)

==> picture [81 x 76] intentionally omitted <==

EQUITY & LIABILITIES(Rs. Crs.)	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18
EquityShare Capital	9.7	9.7	9.7	7.8	7.8
Other Equity	259.4	163.7	119.6	67.6	46.4
Total Equity	269.1	173.4	129.3	75.3	54.1
Non-Current Liabilities
Financial Liabilities
i. Borrowings	47.4	35.4	19.5	11.3	8.3
ii. Other Financial Liabilities	5.0	5.0	4.7	4.7	4.8
iii. Lease Liability	0.3	2.8	6.2	0.0	0.0
Provisions	12.4	10.2	7.9	1.9	2.3
Deferred Tax Liabilities(net)	0.2	1.5	0.0	0.0	0.0
Total Non-Current Liabilities	65.3	55.0	38.4	17.8	15.3
Financial Liabilities
i. Borrowings	6.6	16.3	93.1	84.7	69.2
ii. Trade Payables
Total outstandingdues of micro enterprises and small enterprises	7.0	3.9	0.0	0.0	0.0
Total outstandingdues of other than micro enterprises & small enterprises	134.0	109.2	117.1	77.8	76.0
iii. Other Financial Liabilities	18.7	15.3	10.8	11.1	10.1
iv. Lease Liability	2.8	3.4	3.4	0.0	0.0
Provisions	4.9	4.6	6.6	3.4	3.6
Other current Liabilities	12.4	9.5	8.7	5.2	7.1
Current Tax Liabilities(net)	0.7	1.6	0.0	4.2	2.6
Total Current Liabilities	187.0	163.7	239.8	186.3	168.5
TOTAL EQUITY & LIABILITIES	521.4	392.1	407.5	279.5	238.0

27

==> picture [56 x 41] intentionally omitted <==

Historical Balance Sheet (Assets)

==> picture [81 x 76] intentionally omitted <==

ASSETS (Rs. Crs.)	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18
Non-Current Assets
Property,plant and equipment	111.8	93.8	72.7	24.1	22.4
Intangible assets	0.6	0.4	0.6	0.4	0.5
Capital work-in-progress	40.9	13.4	30.6	9.6	2.1
Right of use assets	2.8	5.8	9.3	0.0	0.0
Financial Assets
i. Investments	0.0	0.0	0.0	0.0	0.0
ii. Loans	0.2	0.3	10.3	7.8	2.7
iii. Other financial assets	9.1	11.3	0.0	0.0	0.0
Deferred tax assets (net)	0.0	0.0	0.6	0.7	2.8
Other non-current assets	35.3	6.5	10.1	4.4	9.4
Total Non Current Assets	200.6	131.5	134.2	47.0	39.8
Current Assets
Inventories	115.6	94.4	122.5	94.3	94.2
Financial Assets
i. Trade Receivables	151.6	124.5	107.0	103.2	80.8
ii. Cash and cash equivalent	11.6	6.2	4.3	3.7	3.7
iii. Bank balances	15.0	7.0	12.1	3.9	3.8
iv. Loans	0.4	0.3	0.3	0.0	0.0
Other current assets	26.7	28.2	27.2	27.4	15.7
Total Current Assets	320.8	260.6	273.3	232.5	198.2
TOTAL ASSETS	521.4	392.1	407.5	279.5	238.0

28

==> picture [56 x 41] intentionally omitted <==

Historical Cash Flows

==> picture [81 x 76] intentionally omitted <==

Cash Flow Statement (Rs. Crs.)	Mar-22	FY21	FY20	FY19	FY18
Net Profit Before Tax	95.8	44.2	22.7	21.9	16.5
Adjustments for: Non - Cash Items / Other Investment or Financial Items	51.9	44.3	32.1	26.8	25.6
Operating profit before working capital changes	147.7	88.5	54.8	48.7	42.0
Changes in working capital	-10.2	10.0	2.5	-33.5	-30.4
Cash generated from Operations	137.5	98.5	57.2	15.2	11.6
Direct taxes paid (net of refund)	-33.1	-9.4	-10.1	-10.0	-16.4
Net Cash from Operating Activities	104.4	89.1	47.1	5.2	-4.8
Net Cash from Investing Activities	-95.9	-8.5	-42.5	-13.0	-8.8
Net Cash from Financing Activities	-3.1	-78.6	-4.2	7.7	14.4
Net Decrease in Cash and Cash equivalents	5.4	1.9	0.4	-0.1	0.7
Add: Cash & Cash equivalents at the beginning of the period	6.2	4.3	3.9	3.7	3.0
Cash & Cash equivalents at the end of the period	11.6	6.2	4.3	3.7	3.7

29

==> picture [102 x 75] intentionally omitted <==

==> picture [162 x 110] intentionally omitted <==

THANK YOU

Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519

==> picture [293 x 12] intentionally omitted <==

Mr. Avik Das – Investor Relations avik.das@guficbio.com

Investor Relations Advisors: Strategic Growth Advisors (SGA) CIN: U74140MH2010PTC204285 Mr. Deven Dhruva / Mr. Jigar Kavaiya deven.dhruva@sgapl.net / jigar.kavaiya@sgapl.net Tel: +91 9833373300 / +91 9920602034

Tel: +91 22 67261000